pirenzepine has been researched along with Acathisia, Drug-Induced in 27 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 9.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 9.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 9.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 9.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "Olanzapine is a newly developed atypical neuroleptic with a marked affinity to the 5-HT2, D2 and D4 dopamine receptors." | 5.30 | Severe akathisia during olanzapine treatment of acute schizophrenia. ( Bachmann, S; Gerdsen, I; Jauss, M; Mundt, C; Pantel, J; Schröder, J, 1998) |
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 5.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 5.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 5.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 5.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| " Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol." | 4.79 | Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997) |
| "Olanzapine is a recently introduced atypical neuroleptic agent for which little information is available on its use in children." | 2.69 | Open-label olanzapine treatment in five preadolescent children. ( King, BH; Krishnamoorthy, J, 1998) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| " Risk factors are a high dosage of antipsychotics, akathisia in a previous treatment, and diabetes mellitus." | 2.41 | [Drug-induced akathisia]. ( van Harten, PN, 2002) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| "Olanzapine is a newly developed atypical neuroleptic with a marked affinity to the 5-HT2, D2 and D4 dopamine receptors." | 1.30 | Severe akathisia during olanzapine treatment of acute schizophrenia. ( Bachmann, S; Gerdsen, I; Jauss, M; Mundt, C; Pantel, J; Schröder, J, 1998) |
| "Olanzapine proved to be an adequate treatment choice for NIA patients." | 1.30 | Measuring neuroleptic-induced akathisia by three-channel actometry. ( Holi, M; Lauerma, H; Markkula, J; Rimon, R; Tuisku, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (62.96) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, R | 1 |
| Saharan, A | 1 |
| Rosenheck, R | 1 |
| Perlick, D | 1 |
| Bingham, S | 1 |
| Liu-Mares, W | 1 |
| Collins, J | 1 |
| Warren, S | 1 |
| Leslie, D | 1 |
| Allan, E | 1 |
| Campbell, EC | 2 |
| Caroff, S | 1 |
| Corwin, J | 1 |
| Davis, L | 1 |
| Douyon, R | 1 |
| Dunn, L | 1 |
| Evans, D | 1 |
| Frecska, E | 1 |
| Grabowski, J | 1 |
| Graeber, D | 1 |
| Herz, L | 1 |
| Kwon, K | 1 |
| Lawson, W | 1 |
| Mena, F | 1 |
| Sheikh, J | 1 |
| Smelson, D | 1 |
| Smith-Gamble, V | 1 |
| Beasley, CM | 2 |
| Tollefson, G | 1 |
| Tran, P | 1 |
| Satterlee, W | 1 |
| Sanger, T | 1 |
| Hamilton, S | 1 |
| Tollefson, GD | 2 |
| Tran, PV | 1 |
| Nemeroff, CB | 1 |
| Casey, DE | 1 |
| Kurzthaler, I | 1 |
| Hummer, M | 1 |
| Kohl, C | 1 |
| Miller, C | 1 |
| Fleischhacker, WW | 1 |
| Conley, RR | 2 |
| Tamminga, CA | 1 |
| Bartko, JJ | 1 |
| Richardson, C | 1 |
| Peszke, M | 1 |
| Lingle, J | 1 |
| Hegerty, J | 1 |
| Love, R | 1 |
| Gounaris, C | 1 |
| Zaremba, S | 1 |
| Krishnamoorthy, J | 1 |
| King, BH | 1 |
| Jauss, M | 1 |
| Schröder, J | 1 |
| Pantel, J | 1 |
| Bachmann, S | 1 |
| Gerdsen, I | 1 |
| Mundt, C | 1 |
| Meyer, JM | 1 |
| Marsh, J | 1 |
| Simpson, G | 1 |
| John, V | 1 |
| Rapp, M | 1 |
| Pies, R | 1 |
| Linazasoro, G | 1 |
| Gorospe, A | 1 |
| Rodríguez, MC | 1 |
| Obeso, JA | 1 |
| Breier, A | 1 |
| Hamilton, SH | 1 |
| Tohen, M | 1 |
| Sanger, TM | 1 |
| McElroy, SL | 1 |
| Chengappa, KN | 1 |
| Daniel, DG | 1 |
| Petty, F | 1 |
| Centorrino, F | 1 |
| Wang, R | 1 |
| Grundy, SL | 1 |
| Greaney, MG | 1 |
| Jacobs, TG | 1 |
| David, SR | 1 |
| Toma, V | 1 |
| Bonin, MM | 1 |
| Burkhart, KK | 1 |
| Tuisku, K | 1 |
| Lauerma, H | 1 |
| Holi, M | 1 |
| Markkula, J | 1 |
| Rimon, R | 1 |
| Knoch, H | 1 |
| Hofmann, M | 1 |
| Seifritz, E | 1 |
| Schulz, SC | 1 |
| Simpson, GM | 1 |
| Meltzer, HY | 1 |
| Ishigooka, J | 2 |
| Murasaki, M | 1 |
| Miura, S | 2 |
| Inada, T | 1 |
| van Harten, PN | 1 |
| Caroff, SN | 1 |
| Mann, SC | 1 |
| Sullivan, KA | 1 |
| Kingsbury, SJ | 1 |
| Castelo, C | 1 |
| Abulseoud, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774] | Phase 4 | 600 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
10 reviews available for pirenzepine and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Atypical antipsychotics: experience and use in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; | 2002 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
[Drug-induced akathisia].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Complications; D | 2002 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
8 trials available for pirenzepine and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Met | 2003 |
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon | 1996 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; | 1998 |
Open-label olanzapine treatment in five preadolescent children.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod | 1998 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben | 1999 |
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepin | 1999 |
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Female; Humans; Japa | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind | 2001 |
9 other studies available for pirenzepine and Acathisia, Drug-Induced
| Article | Year |
|---|---|
Propranolol treatment of olanzapine-induced akathisia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; | 1997 |
Severe akathisia during olanzapine treatment of acute schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Female; Humans; Middle Aged; | 1998 |
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, D | 1998 |
Aggression, agitation, and mania with olanzapine.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1998 |
Alleviation of sulpiride induced tardive akathisia by olanzapine: case report.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Female; Humans; Middle Aged; Olanzap | 1998 |
Olanzapine overdose in a 1-year-old male.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Humans; Infant; Male; | 1999 |
Measuring neuroleptic-induced akathisia by three-channel actometry.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Diagnos | 1999 |
[Olanzapine as an alternative in clozapine-induced akathisia?].
Topics: Adult; Akathisia, Drug-Induced; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; | 1999 |
Quetiapine for olanzapine-induced galactorrhea.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Ther | 2002 |